Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

Summary

This study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

• References

• 1 McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989; 73: 506-513
• 2 Exner T, McRea J. Studies on the relationship between antiphospholipid antibodies and the lupus anticoagulant. Blood Coagul Fibrinol 1990; 1: 17-21
• 3 Brandt JT, Triplett DA. The sensitivity of different coagulation reagents to the presence of lupus anticoagulant. Arch Pathol Lab Med 1987; 111: 120-124
• 4 Falcon CR, Hoffer AM, Forastiero RR, Carreras LO. Clinical significance of various ELISA assays for detecting antiphospholipid antibodies. Thromb Haemostas 1990; 64: 21-25
• 5 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
• 6 Triplett DA. Laboratory diagnosis of lupus anticoagulants. Semin Thromb Haemostas 1990; 16: 182-192
• 7 Triplett DA, Brandt JT. Lupus anticoagulant: Misnomer, paradox, riddle epiphenomenon. Hematol Pathol 1988; 2: 121-143
• 8 Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20: 231-236
• 9 Asherson RA, Harris EN. Anticardiolipin antibodies: clinical associations. Postgrad Med J 1986; 62: 1081-1085
• 10 Creagh MD, Greaves M. Lupus anticoagulant. Blood Rev 1991; 5: 162-167
• 11 Stasi R, Venditti A, Del Poeta G, Tribalto M, Coppetelli U, Zaccari G, Papa G. High Interleukin-6 plasma levels in acute promyelocytic leukemia. Ann Hematol 1992; 64: 303-304
• 12 Stasi R, Conforti M, Del Poeta G, Simone MD, Coppetelli U, Tribalto M, Cantonetti M, Perrotti A, Venditti A, Papa G. Soluble factors levels in the initial staging of high-grade non-Hodgkin’s lymphomas. Haematologica 1992; 77: 518-521
• 13 Guglielmi C, Amadori S, Anselmo AP, Baroni CD, Biagini C, Cimino G, Papa G, Mandelli F. Sequential combination chemotherapy of high-grade non-Hodgkin’s lymphoma with 5-Fluorouracil, Methotrexate, Cytosine-Arabinoside, Cyclophos-phamide, Doxorubicin, Vincristin and Prednisone (F-MACHOP). Cancer Inv 1987; 5: 159-169
• 14 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemostas 1991; 65: 320-322
• 15 Triplett DA, Brandt JT, Kaczor D, Scaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
• 16 Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 219-222
• 17 Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, Hagemeister FB, Cabanillas F. A new Serologie staging system for large-cell lymphomas based on initial Beta2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989; 10: 1518-1527
• 18 Alarcon-Segovia D. The pathophysiology of antiphospholipid antibodies. Semin Clin Immunol 1991; 1: 11-19
• 19 Gleicher M, Friberg J. IgM gammopathy and the lupus anticoagulant. JAMA 1985; 253: 3278-3282
• 20 Ciaudo M, Horellou MH, Audouin J, De Carbonnieres C, Conard J, Samama M. Lupus anticoagulant associated with primary malignant lymphoplasmocytic lymphoma of the spleen: a report of four patients. Am J Hematol 1991; 38: 271-276
• 21 Bellotti V, Gamba G, Merlini G, Montani N, Bucciarelli E, Stoppini M, Ascari E. Study of three patients with monoclonal gammopathies and lupus-like anticoagulants. Br J Haematol 1989; 73: 221-227
• 22 Pizzolo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol 1987; 67: 377-380